Allied Market Research

Factors that drive the growth of the global oncology/cancer drugs market include rise in awareness among the population about the treatment options of cancer, increase in prevalence of cancer disease, and surge in geriatric population. However, adverse effects related to cancer drugs is expected to hamper the growth of market.

WILMINGTON, Del., Feb. 10, 2026 /PRNewswire/ -- According to a new report published by Allied Market Research, titled, "Global Oncology/Cancer Drugs Market by Drug Class Type, Indication, and Region: Global Opportunity Analysis and Industry Forecast, 2024–2033," The oncology drugs market size was valued at $167.0 billion in 2023, and is projected to reach $335.2 billion by 2033, registering a CAGR of 7.2% from 2024 to 2033. Cancer is caused when the cells present in the body grow at an uncontrolled rate leading to the formation of a tumor. Cancer has different stages based on its progression. Metastasis is the final stage of the disease, which is marked by the invasion of tumor into others parts of body. The management of cancer in patients requires the use of different drugs such as hormonal therapy, immunotherapy, targeted therapy, and chemotherapy.

Request Sample of the Report on Global Oncology/Cancer Drugs Market 2033 - https://www.alliedmarketresearch.com/request-sample/121

Introduction and Dynamics

Rise in geriatric population, surge in prevalence of cancer, early screening of the cancer, and higher number of R&D activities to develop cancer therapeutics significantly contribute toward the growth of the market. Promising drugs in late stage of pipeline with high potential of emerging economies are further expected to provide lucrative opportunities for market expansion. However, adverse effects related to cancer drugs impede the oncology drugs market growth.

Market Segmentation

By drug class type, targeted therapy segment is anticipated to grow with the largest share throughout the forecast period. This is attributed to the identification of molecular targets of cancer cells, fewer adverse effects, and availability of number of targeted therapeutics. Recent advances in cellular technology have contributed to improve the understanding of tumor cells and their metabolism at molecular level, thus driving the need for targeted drug therapies for cancer treatment. On the other side, the demand for immunotherapy is projected to exhibit the fastest market growth during the forecast period due to its affectivity, and expected launch of pipeline immunotherapies.